Biological, Chemical and Nuclear Terrorism: Potential Diagnostic and Treatment Costs to the U.S.

• STUDY GOALS AND OBJECTIVES
• REASONS FOR STUDY
• SCOPE OF STUDY
• METHODOLOGY AND INFORMATION SOURCES
• ANALYST CREDENTIALS
• RELATED BCC PUBLICATIONS
• REPORTS
• MONTHLY NEWSLETTERS
• BCC ON-LINE SERVICES

EXECUTIVE SUMMARY

Summary Table: MARKET SIZE OF U.S. TREATMENTS OF THREE SELECTED HYPOTHETICAL INCIDENTS BASED ON THE NEW YORK METROPOLITAN POPULATION AND POTENTIAL MASS CASUALTY RATES, THROUGH 2007

INDUSTRY OVERVIEW

• HISTORICAL PERSPECTIVE OF BIOTERRORISM
• TYPES OF BIOTERRORISM
• BIOLOGICAL
• CHEMICAL
• NUCLEAR
• MEDICAL ASPECTS OF BIOLOGICAL WARFARE
• Table 1. BIOTERRORISM AGENTS CATEGORIES AS CLASSIFIED BY THE CENTER FOR DISEASE CONTROL AND INFECTION
• Table 1. (CONTINUED)
• PREPAREDNESS
• PREPAREDNESS (CONTINUED)
• LEGISLATIVE AND REGULATORY ENVIRONMENT
• HOMELAND DEFENSE
• HOMELAND DEFENSE (CONTINUED)
• Homeland Defense (Continued)
• Homeland Defense (Continued)
• MARCH-IN THREAT
• ECONOMIC IMPACT OF BIOTERRORISM
• Table 2. COSTS OF HOSPITALIZATION AND OUTPATIENT VISITS FOLLOWING A BIOTERRORIST ATTACK
• Table 2. (CONTINUED)
• Table 3. COSTS OF PROPHYLAXIS FOLLOWING A BIOTERRORIST ATTACK
• Table 3. (CONTINUED)
• Table 4. COSTS (IN MILLIONS) OF BIOTERRORIST ATTACK WITH NO POSTEXPOSURE PROPHYLAXIS
• Table 4. (CONTINUED)

INTERNATIONAL BIOTERRORISM AND TERRORIST ORGANIZATIONS

• ABU SAYYAF
• AL-GAMA'A AL-ISLAMIYYAH
• AL-QAEDA
• AL-QAEDA (CONTINUED)
• AL-QAEDA (CONTINUED)
• AL-QAEDA (CONTINUED)
• AL-QAEDA (CONTINUED)
• AL-QAEDA (CONTINUED)
• AL-QAEDA (CONTINUED)
• ARMATA CORSA
• GIA
• AUM
• THE BASQUE FATHERLAND AND LIBERTY GROUP
• THE BASQUE FATHERLAND AND LIBERTY GROUP (CONTINUED)
• THE DEMOCRATIC FRONT FOR LIBERATION OF PALESTINE (DFLP)
• THE DEMOCRATIC FRONT FOR LIBERATION OF PALESTINE (CONTINUED)
• ABU NIDAL ORGANIZATION (ANO)
• FATAH-RC
• TANZIM
• TANZIM (CONTINUED)
• TANZIM (CONTINUED)
• TANZIM (CONTINUED)
• FORCE 17
• FORCE 17 (CONTINUED)
• FORCE 17 (CONTINUED)
• HAMAS
• HAMAS (CONTINUED)
• HAMAS (CONTINUED)
• HUM
• HUM (CONTINUED)
• HIZBALLAH
• HIZBALLAH (CONTINUED)
• THE HIZB-UL MUJAHEDIN
• THE HIZB-UL MUJAHEDIN (CONTINUED)
• IRA
• JAMAAT UL-FUQRA
• JAPANESE RED ARMY
• JIHAD
• JIHAD (CONTINUED)
• KACH
• KURDISTAN WORKER'S PARTY
• KURDISTAN WORKER'S PARTY (CONTINUED)
• KURDISTAN WORKER'S PARTY (CONTINUED)
• KURDISTAN WORKER'S PARTY (CONTINUED)
• KURDISTAN WORKER'S PARTY (CONTINUED)
• KURDISTAN WORKER'S PARTY (CONTINUED)
• KURDISTAN WORKER'S PARTY (CONTINUED)
• LASHKAR-E-TOIBA
• LASHKAR-E-TOIBA (CONTINUED)
• LAUTARO YOUTH MOVEMENT (MJL)
• LTTE
• LOYALIST VOLUNTEER FORCE
• MANUEL RODRIQUEZ PATRIOTIC FRONT
• MUJAHEDIN-E KHALQ ORGANIZATION
• NATIONAL LIBERATION ARMY (ELN) COLOMBIA
• NATIONAL LIBERATION FRONT OF CORSICA (FLNC)
• NEW PEOPLE'S ARMY
• POPULAR LIBERATION FRONT
• POPULAR LIBERATION FRONT (CONTINUED)
• POPULAR LIBERATION FRONT (CONTINUED)
• PALESTINIAN ISLAMIC JIHAD
• PALESTINIAN ISLAMIC JIHAD (CONTINUED)
• KHMER ROUGE
• POPULAR FRONT FOR THE LIBERATION OF PALESTINE - GENERAL COMMAND
• POPULAR FRONT FOR THE LIBERATION OF PALESTINE -�c.(CONTINUED)
• POPULAR FRONT FOR THE LIBERATION OF PALESTINE -�c.(CONTINUED)
• PALESTINIAN POPULAR STRUGGLE FRONT
• QIBLA
• REAL IRA
• RED ARMY FACTION (RAF)
• RED ARMY FACTION (RAF) (CONTINUED)
• BRIGATE ROSSE (RED BRIGADE)
• REVOLUTIONARY ORGANIZATION 17 NOVEMBER
• SIPAH-E-SAHABA PAKISTAN (SSP)
• SIPAH-E-SAHABA PAKISTAN (SSP) (CONTINUED)
• SIPAH-E-SAHABA PAKISTAN (SSP) (CONTINUED)
• TUPAC AMARU
• Table 5. TERRORIST ORGANIZATIONS WORLDWIDE
• Table 5. (CONTINUED)
• Table 5. (CONTINUED)

BIOLOGICAL AGENTS

• INTRODUCTION
• TYPES OF BIOLOGICAL AGENTS
• ANTHRAX
• Treatment
• BRUCELLOSIS
• Treatment
• EBOLA
• Treatment
• HEMORRHAGIC FEVERS
• Treatment
• PLAGUE
• Treatment
• Q FEVER
• Treatment
• SMALLPOX
• Treatment
• TULAREMIA
• Treatment
• TOXIC AGENTS
• Botulism
• Treatment
• Ricin Toxin
• Treatment
• OTHERS
• Others (Continued)
• Others (Continued)
• Others (Continued)
• Others (Continued)
• Others (Continued)
• MARKET SIZE AND GROWTH
• Table 6. MARKET SIZE OF U.S. TREATMENTS OF ANTHRAX BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 7. MARKET SIZE OF U.S. TREATMENTS OF BRUCELLOSIS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 7. (CONTINUED)
• Table 8. MARKET SIZE OF U.S. TREATMENTS OF HEMMORRHAGIC FEVER BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 9. MARKET SIZE OF U.S. TREATMENTS OF PLAGUE BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 9. (CONTINUED)
• Table 10. MARKET SIZE OF U.S. TREATMENTS OF Q-FEVER BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 10. (CONTINUED)
• Table 11. MARKET SIZE OF U.S. TREATMENTS OF SMALLPOX BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 12. MARKET SIZE OF U.S. TREATMENTS OF TULAREMIA BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• COMPETITIVE ANALYSIS
• Table 13. BIOLOGICAL AGENTS MANUFACTURER MARKET SHARE BY REVENUES, 2001
• Figure 1. BIOLOGICAL AGENTS MANUFACTURER MARKET SHARE BY REVENUES, 2001
• MARKET ANALYSIS

CHEMICAL AGENTS

• INTRODUCTION
• TYPES OF CHEMICAL AGENTS
• BLISTER AGENTS
• BLOOD AGENTS
• CHOKING AGENTS
• NERVE AGENTS
• MARKET SIZE AND GROWTH
• Table 14. MARKET SIZE OF U.S. TREATMENTS OF BLISTER AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 14. (CONTINUED)
• Table 15. MARKET SIZE OF U.S. TREATMENTS OF BLOOD AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 15. (CONTINUED)
• Table 16. MARKET SIZE OF U.S. TREATMENTS OF NERVE AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012
• Table 16. (CONTINUED)

NUCLEAR AGENTS

• INTRODUCTION
  • INTRODUCTION (CONTINUED)
  • INTRODUCTION (CONTINUED)
• CLASSES OF RADIATION
  • CLASSES OF RADIATION (CONTINUED)
  • CLASSES OF RADIATION (CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
  • CLASSES OF RADIATION CONTINUED)
• MARKET SIZE AND GROWTH
• Table 17. MARKET SIZE OF U.S. TREATMENTS OF NUCLEAR AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

BIOTERRORISM TREATMENT MARKET ANALYSIS

• Table 18. TREATMENT COSTS OF BIOLOGICAL, CHEMICAL AND NUCLEAR TERRORISM, BASED ON U.S. TREATMENT, 2002 ($)
• INDUSTRY PARTICIPANTS BY PRODUCT TYPE
• Table 19. INDUSTRY PARTICIPANTS BY PRODUCT TYPE
• Table 19. (CONTINUED)
• STRATEGIES BASED ON PRODUCTS
  • STRATEGIES BASED ON PRODUCTS (CONTINUED)
  • STRATEGIES BASED ON PRODUCTS (CONTINUED)
  • STRATEGIES BASED ON PRODUCTS (CONTINUED)
  • STRATEGIES BASED ON PRODUCTS (CONTINUED)

PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY PROFILES

• ABGENIX, INC
• ACAMBIS PLC
• ADVANCED BIOSYSTEMS
• AVENTIS PASTEUR
• BAXTER INTERNATIONAL, INC.
• BAYER CORPORATION
• BIOPORT CORPORATION
• CORIXA CORPORATION
• CRUCELL N.V.
• GILEAD SCIENCES, INC.
• PFIZER, INC.
• PHARMACIA CORPORATION
• POWDERJECT PHARMACEUTICALS PLC
• VICAL, INC.
• WYETH

GOVERNMENT AND HEALTH AGENCY PROFILES

• CENTERS FOR DISEASE CONTROL AND PREVENTION
• FOOD AND DRUG ADMINISTRATION/NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH
• DEPARTMENT OF HEALTH AND HUMAN SERVICES
• NATIONAL INSTITUTES OF HEALTH
• OFFICE OF HOMELAND SECURITY
• TASK FORCE ON EMERGENCY PREPAREDNESS

APPENDIX

• U.S. POPULATION GROWTH
• Table 20. POPULATION 2001, 2005, AND 2015 (THOUSANDS)
• COMPANY LIST
• Table 21. COMPANY LIST
• Table 21. (CONTINUED)
• Table 21. (CONTINUED)
• Table 21. (CONTINUED)
• Table 21. (CONTINUED)
• Table 21. (CONTINUED)

LIST OF TABLES

Table 1 BIOTERRORISM AGENTS CATEGORIES AS CLASSIFIED BY THE CENTER FOR DISEASE CONTROL AND INFECTION

Table 2 COSTS OF HOSPITALIZATION AND OUTPATIENT VISITS FOLLOWING A BIOTERRORIST ATTACK

Table 3 COSTS OF PROPHYLAXIS FOLLOWING A BIOTERRORIST ATTACK

Table 4 COSTS (IN MILLIONS) OF BIOTERRORIST ATTACK WITH NO POSTEXPOSURE PROPHYLAXIS

Table 5 TERRORIST ORGANIZATIONS WORLDWIDE

Table 6 MARKET SIZE OF U.S. TREATMENTS OF ANTHRAX BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 7 MARKET SIZE OF U.S. TREATMENTS OF BRUCELLOSIS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 8 MARKET SIZE OF U.S. TREATMENTS OF HEMMORRHAGIC FEVER BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 9 MARKET SIZE OF U.S. TREATMENTS OF PLAGUE BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 10 MARKET SIZE OF U.S. TREATMENTS OF Q-FEVER BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 11 MARKET SIZE OF U.S. TREATMENTS OF SMALLPOX BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 12 MARKET SIZE OF U.S. TREATMENTS OF TULAREMIA BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 13 BIOLOGICAL AGENTS MANUFACTURER MARKET SHARE BY REVENUES, 2001

Table 14 MARKET SIZE OF U.S. TREATMENTS OF BLISTER AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 15 MARKET SIZE OF U.S. TREATMENTS OF BLOOD AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 16 MARKET SIZE OF U.S. TREATMENTS OF NERVE AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 17 MARKET SIZE OF U.S. TREATMENTS OF NUCLEAR AGENTS BASED ON THE TOP THREE U.S. METROPOLITAN POPULATIONS AND POTENTIAL MASS CASUALTY RATES, THROUGH 2012

Table 18 TREATMENT COSTS OF BIOLOGICAL, CHEMICAL AND NUCLEAR TERRORISM, BASED ON U.S. TREATMENT, 2002 ($)

Table 19 INDUSTRY PARTICIPANTS BY PRODUCT TYPE

Table 20 POPULATION 2001, 2005, AND 2015 (THOUSANDS)

Table 21 COMPANY LIST

LIST OF FIGURES